Etrolizumab
Etrolizumab is a monoclonal antibody designed for the treatment of Ulcerative colitis and Crohn's disease. It is developed by Genentech, a member of the Roche Group.
Mechanism of Action[edit | edit source]
Etrolizumab is a humanized monoclonal antibody that selectively binds to the beta7 subunit of the integrin heterodimer. This binding inhibits the interaction of the beta7 subunit with MAdCAM-1 and E-cadherin, thereby preventing the migration of leukocytes into gut tissues.
Clinical Trials[edit | edit source]
Etrolizumab has been studied in Phase III clinical trials for the treatment of moderate to severe ulcerative colitis and Crohn's disease. The results of these trials are pending.
Side Effects[edit | edit source]
The most common side effects of etrolizumab include nausea, headache, fatigue, and abdominal pain. Serious side effects can include infections, infusion reactions, and liver problems.
See Also[edit | edit source]
Etrolizumab Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD